Aptevo Therapeutics Inc (APVO) concluded trading on Wednesday at a closing price of $0.38, with 118.5 million shares of worth about $45.03 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -95.13% during that period and on May 21, 2025 the price saw a gain of about 22.62%. Currently the company’s common shares owned by public are about 8.11M shares, out of which, 7.85M shares are available for trading.
Stock saw a price change of 15.15% in past 5 days and over the past one month there was a price change of -45.20%. Year-to-date (YTD), APVO shares are showing a performance of -91.18% which decreased to -98.72% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.24 but also hit the highest price of $32.93 during that period. The average intraday trading volume for Aptevo Therapeutics Inc shares is 3.09 million. The stock is currently trading -12.38% below its 20-day simple moving average (SMA20), while that difference is down -65.50% for SMA50 and it goes to -93.83% lower than SMA200.
Aptevo Therapeutics Inc (NASDAQ: APVO) currently have 8.11M outstanding shares and institutions hold larger chunk of about 7.97% of that.
The stock has a current market capitalization of $3.08M and its 3Y-monthly beta is at 5.76. It has posted earnings per share of -$88.45 in the same period. It has Quick Ratio of 0.67. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APVO, volatility over the week remained 37.39% while standing at 17.07% over the month.
Stock’s fiscal year EPS is expected to rise by 81.87% while it is estimated to increase by 8.52% in next year. EPS is likely to shrink at an annualized rate of 51.40% for next 5-years, compared to annual growth of 80.96% made by the stock over the past 5-years.
Coverage by Piper Jaffray stated Aptevo Therapeutics Inc (APVO) stock as an Overweight in their note to investors on October 05, 2017, suggesting a price target of $6 for the stock.
